Shares of OpGen Inc (NASDAQ:OPGN) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price target of $30.00 for the company and are anticipating that the company will post ($2.60) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 62 out of 255 based on the ratings given to its competitors.

A number of brokerages have recently weighed in on OPGN. Aegis set a $20.00 price objective on shares of OpGen and gave the stock a “buy” rating in a research note on Monday, September 9th. ValuEngine raised shares of OpGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 2nd.

An institutional investor recently bought a new position in OpGen stock. Susquehanna International Group LLP bought a new position in shares of OpGen Inc (NASDAQ:OPGN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 71,942 shares of the medical research company’s stock, valued at approximately $28,000. Susquehanna International Group LLP owned 0.41% of OpGen as of its most recent SEC filing.

Shares of OPGN stock traded up $0.51 during midday trading on Tuesday, reaching $6.34. 16,585 shares of the company were exchanged, compared to its average volume of 46,426. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.78 and a current ratio of 0.89. The company’s 50 day moving average price is $7.07 and its two-hundred day moving average price is $2.08. OpGen has a 12 month low of $4.20 and a 12 month high of $40.60. The company has a market cap of $5.14 million, a P/E ratio of -0.14 and a beta of 0.78.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($3.00) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.20) by $0.20. The firm had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.10 million. OpGen had a negative net margin of 402.07% and a negative return on equity of 398.16%. As a group, sell-side analysts predict that OpGen will post -12.4 earnings per share for the current year.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Story: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.